Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,281 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Candidiasis, Mycoses, HIV Infections
Interventions: Clotrimazole, Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 25
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 18 more

Conditions: HIV/AIDS, Gonorrhea, Chlamydia
Interventions: Keep It Up! 3.0; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 34 Years · Male only
Enrollment: 2,249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Family-based HIV prevention program; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 13 Years to 18 Years
Enrollment: 718 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Group B Streptococcal Infection
Interventions: Vaginal and rectovaginal swab cultures; Biological
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: HIV/AIDS
Interventions: NIDA Standard for HIV Prevention; Behavioral
Lead sponsor: Michele Staton; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: COVID-19
Interventions: AZD7442, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 50
States / cities: Guntersville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 42 more

Conditions: Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Interventions: VRC-HIVRGP096-00-VP, Alum Adjuvant; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sexually Transmitted Infections, Gay, Pre Exposure Prophylaxis
Interventions: Quantitative survey, HIV and STI testing, Qualitative Assessment; Behavioral · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 675 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: San Diego, California • Atlanta, Georgia • Chicago, Illinois

Conditions: HIV Infections
Interventions: Project Enhance, Standard prevention case management (PCM); Behavioral
Lead sponsor: Fenway Community Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV, Acquired Immunodeficiency Syndrome, Alcoholism, Alcoholic Intoxication, Substance-Related Disorders
Interventions: Motivational Interviewing, Email Feedback, Usual Care; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 100 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Influenza, Healthy
Interventions: FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018); Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 24 Months to 47 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 12
States / cities: Savannah, Georgia • Bardstown, Kentucky • St Louis, Missouri + 9 more

Conditions: HIV Infections
Interventions: Skills Building with Motivational Interviewing, Skills Building; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions: Famotidine, Celecoxib, Placebo; Drug
Lead sponsor: Leidos Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more

Conditions: Central Line Associated Blood Stream Infections (CLABSI)
Interventions: Infection Preventionist Led Best Practices Reminders; Behavioral
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Anchorage, Alaska • Apple Valley, California • Burbank, California + 15 more

Conditions: Respiratory Syncytial Virus Infection
Interventions: RSV Polyclonal Immunoglobulin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Herpes Simplex
Interventions: Valaciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia, COVID-19 Infection
Interventions: Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1; Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: HIV Infections, HIV
Interventions: Information provision, Weekly quizzes, Rewards for testing HIV-negative; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: SARS-CoV-2 Infection
Interventions: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant); Biological · Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: COVID 19
Interventions: MR or M-M-R II ® vaccine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 3,411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Rabies
Interventions: Active rabies vaccine (US-FDA approved); Drug
Lead sponsor: Kamada, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Social Stigma, Substance Use Disorders, HIV Infections, Physician-Patient Relations
Interventions: Substance use stigma training; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
Interventions: Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group; Behavioral
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Urinary Tract Infection
Interventions: E. coli 83972 coated urinary catheter; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)

A Pragmatic Trial of Two Strategies for Implementing an Effective eHealth HIV Prevention Program (Keep It Up! 3.0)

HIV Prevention for Youth With Severe Mental Illness

Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization

Social Media HIV Prevention Intervention for High Risk Rural Women

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men

Enhancing HIV Prevention by Using Behavioral Intervention Among HIV-Infected Men

Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

HIV Prevention With the Mentally Ill

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction

Prevention of RSV Infections in Bone Marrow Transplant Recipients

Valaciclovir to Prevent Transmission of Herpes Simplex Virus

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

Using Mobile Technology and Incentives With Men Who Have Sex With Men and Transgender Women for HIV Prevention

PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19

CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION

Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care

Culturally Tailored HPV Psychoeducational Multimedia Intervention

Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study